open access

Vol 3, No 3 (2007)
Review paper
Published online: 2007-05-24
Get Citation

Evolving therapy options for B-cell low grade lymphoma

Ewa Kalinka-Warzocha
Onkol. Prak. Klin 2007;3(3):140-149.

open access

Vol 3, No 3 (2007)
REVIEW ARTICLES
Published online: 2007-05-24

Abstract

This article presents actual treatment opinions of low grade B-cell lymphomas. The precise diagnosis of lymphoma subtype is necessary for adequate treatment planning and identification of prognostic factors for adverse clinical outcome, as well as predictive factors for particular treatment response. Taking into consideration that low grade lymphomas constitute a heterogenic group of entities, the differences in clinical course have been described. The most adequate induction treatment for follicular lymphoma is chemoimmunotherapy with rituximab. The optimal chemotherapy schedule has not been established yet in clinical trials but their results are expected during the years to come. Independently of induction therapy, patients with follicular lymphoma beneficiate from maintenance treatment with rituximab. In splenic marginal zone lymphoma splenectomy remains the first line treatment of choice. In MALT lymphoma chemotherapy, especially based on purine analogs is efficient as well as immunotherapy in chosen patients but antibiotics need to be incorporated in first line therapy. Radiotherapy is a potential treatment option for only local involvement. In nodal marginal zone lymphoma, the same approach as in follicular lymphoma is advised. In lymphoplasmacytic lymphoma chemotherapy is efficient but in cases with blood orhyperviscosity plasmapheresis is advised, while patients with cryoglobulinemia beneficiate from rituximab or/and cyclophosphamide.

Abstract

This article presents actual treatment opinions of low grade B-cell lymphomas. The precise diagnosis of lymphoma subtype is necessary for adequate treatment planning and identification of prognostic factors for adverse clinical outcome, as well as predictive factors for particular treatment response. Taking into consideration that low grade lymphomas constitute a heterogenic group of entities, the differences in clinical course have been described. The most adequate induction treatment for follicular lymphoma is chemoimmunotherapy with rituximab. The optimal chemotherapy schedule has not been established yet in clinical trials but their results are expected during the years to come. Independently of induction therapy, patients with follicular lymphoma beneficiate from maintenance treatment with rituximab. In splenic marginal zone lymphoma splenectomy remains the first line treatment of choice. In MALT lymphoma chemotherapy, especially based on purine analogs is efficient as well as immunotherapy in chosen patients but antibiotics need to be incorporated in first line therapy. Radiotherapy is a potential treatment option for only local involvement. In nodal marginal zone lymphoma, the same approach as in follicular lymphoma is advised. In lymphoplasmacytic lymphoma chemotherapy is efficient but in cases with blood orhyperviscosity plasmapheresis is advised, while patients with cryoglobulinemia beneficiate from rituximab or/and cyclophosphamide.
Get Citation

Keywords

follicular lymphoma; lymphoplasmacytic; marginal zone; chemotherapy; immunotherapy; radiotherapy

About this article
Title

Evolving therapy options for B-cell low grade lymphoma

Journal

Oncology in Clinical Practice

Issue

Vol 3, No 3 (2007)

Article type

Review paper

Pages

140-149

Published online

2007-05-24

Bibliographic record

Onkol. Prak. Klin 2007;3(3):140-149.

Keywords

follicular lymphoma
lymphoplasmacytic
marginal zone
chemotherapy
immunotherapy
radiotherapy

Authors

Ewa Kalinka-Warzocha

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl